Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Neoplasms 1Metastatic Pancreatic Adenocarcinoma 1Lymphoma, T-Cell 1Lung Neoplasms 1Head and Neck Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 4Oncolytic Virotherapy 4Cisplatin 4Cetuximab 3Radiotherapy 2Positron Emission Tomography Computed Tomography 2Nivolumab 2Magnetic Resonance Spectroscopy 2Immunohistochemistry 2Fluorouracil 2Erlotinib Hydrochloride 2Docetaxel 2technetium 99m ethylenedicysteine deoxyglucose 1ruxolitinib 1dornase alfa 1avelumab 1alovudine 1Varenicline 1VTX-2337 1Tobacco Use Cessation Devices 1Tetrahydrouridine 1TAK-981 1Ropivacaine 1Raltegravir Potassium 1Pyrimethamine 1Postmortem Imaging 1Positron-Emission Tomography 1Paclitaxel 1Oxycodone 1Neoadjuvant Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Head and Neck Neoplasms × Tetrahydrouridine × Clear all
NCT01479348 2020-06-02

Imaging Study for FdCyd and THU Cancer Treatment

National Institutes of Health Clinical Center (CC)

Phase EARLY_PHASE1 Terminated
5 enrolled 12 charts
BreastGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡